Glecaprevir CAS No.1365970-03-1
GMP ISO FDA
1365970-03-1
Pharmaceutical grade
99%
Shanghai
JINLAN PHARM
25Kg/drum
2022-12-31
additives,pharmaceutical chemicals,organic intermediate,chemical intermediates,Pharmaceutical Intermediates,catalyst
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
Glecaprevir
Other Name:A 1282576.0;(3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2-(difluoromethyl)-1-[(1-methyl-cyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12methanocyclopenta[18,19][1,10,17,3,6]trioxadiaz-acyclononadecino[11,12-b]quinoxaline-10-carboxamide;ABT 493;(1R,2R)-N-[[[(1R,2R)-2-[[4,4-Difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl]oxy]cyclopentyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]cyclopropanecarboxamide cyclic (1→2)-ether;Maviret (trade name,combination with pibrentasvir);
CAS No.:1365970-03-1
Molecular Formula:C38H46F4N6O9S
Exact Mass:838.298
Categories:
Characteristics-
PSA:
203.6
XLogP3:5.9861
Density:1.46 g/cm3 (predict)
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
additives,pharmaceutical chemicals,organic intermediate,chemical intermediates,Pharmaceutical Intermediates,catalyst
-
Location:
hangzhou,zhejiang
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2020
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
